{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:08:58Z","timestamp":1787166538136,"version":"build-2736575974"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder squamous cell carcinoma (SCC) is a rare histological subtype of bladder cancer (1%\u20135% of cases), with radical cystectomy as the primary recommended treatment. However, evidence for neoadjuvant\/adjuvant chemotherapy or immunotherapy remains limited, especially for calculus-associated SCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 45-year-old male with vesical calculus-associated bladder SCC refused surgery and radiotherapy, and discontinued gemcitabine-cisplatin chemotherapy due to severe toxicity. He received tislelizumab (programmed death-1\/PD-1 inhibitor, 200 mg q3w) and achieved a complete response (CR) after 8 cycles. Suprapubic cystolithotomy was safely performed during immunotherapy, and no tumor recurrence was observed for &amp;gt;24 months. Throughout the entire immunotherapy course, no severe immune-related adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tislelizumab monotherapy may be a viable option for surgery-ineligible or chemotherapy-intolerant calculus-associated bladder SCC. Definitive stone removal under immunological tumor control is feasible, supporting further exploration of PD-1 inhibitors in this rare subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1688443","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T10:17:22Z","timestamp":1763720242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Durable complete response to PD-1 inhibitor in vesical calculus-associated squamous cell carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Xingwang","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000534858","article-title":"Metastatic squamous cell carcinoma of the urinary bladder: urgent call for new therapies","volume":"108","author":"Banek","year":"2024","journal-title":"Urol Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020169","article-title":"Squamous cell bladder cancer: A rare histological variant with a demand for modern cancer therapeutics","volume":"17","author":"Bell","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27525","article-title":"Squamous cell carcinoma of the bladder: demographics and outcomes associated with surgery and radiotherapy","volume":"129","author":"Larkins","year":"2024","journal-title":"J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.019","article-title":"Frequent pd-L1 protein expression and molecular correlates in urinary bladder squamous cell carcinoma","volume":"74","author":"Udager","year":"2018","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.02.017","article-title":"Expression and prognostic utility of pd-L1 in patients with squamous cell carcinoma of the bladder","volume":"37","author":"Owyong","year":"2019","journal-title":"Urol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2020.02.12","article-title":"Expression and prognostic value of pd-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma","volume":"9","author":"Liu","year":"2020","journal-title":"Trans Andrology Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.03.019","article-title":"A complete response after pseudo-progression: pembrolizumab for metastatic squamous cell carcinoma (Scc) of the bladder","volume":"17","author":"Kao","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30132686","article-title":"Focus on pd-1\/pd-L1-targeting antibodies in colorectal cancer: are there options beyond dostarlimab, nivolumab, and pembrolizumab? A comprehensive review","volume":"30","author":"Kciuk","year":"2025","journal-title":"Molecules (Basel Switzerland)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1688443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T10:17:22Z","timestamp":1763720242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1688443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":9,"alternative-id":["10.3389\/fimmu.2025.1688443"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1688443","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1688443"}}